ARK Genomic Revolution ETF
ARKG
64 hedge funds and large institutions have $88.1M invested in ARK Genomic Revolution ETF in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 30 increasing their positions, 9 reducing their positions, and 12 closing their positions.
233% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 9
73% more capital invested
Capital invested by funds: $50.8M → $88.1M (+$37.3M)
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
8% more funds holding
Funds holding: 59 → 64 (+5)
2.08% more ownership
Funds ownership: 19.8% → 21.87% (+2.1%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CFA
Carroll Financial Associates
Charlotte,
North Carolina
|
+$6.38M |
| 2 |
BCM
Barometer Capital Management
Toronto,
Ontario, Canada
|
+$2.66M |
| 3 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
+$2.44M |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$2.4M |
| 5 |
Morgan Stanley
New York
|
+$2.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Arlington Capital Management
Arlington Heights,
Illinois
|
-$5.38M |
| 2 |
SI
Stephens Inc
Little Rock,
Arkansas
|
-$2.03M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.1M |
| 4 |
Chevy Chase Trust
Bethesda,
Maryland
|
-$822K |
| 5 |
Financial Engines Advisors
Santa Clara,
California
|
-$705K |
ARKG Hedge Fund Activity: Q1 2019 in Review
64 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q1 2019, worth a combined $88.1M — up 73% from $50.8M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ARKG positions and 12 closed out — a net gain of 5 holders — while 30 added to existing stakes and 9 trimmed.
The largest buyer was Carroll Financial Associates, adding an estimated $6.38M. The largest seller was Arlington Capital Management, exiting entirely with an estimated $5.38M sold.
- 64 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q1 2019, up from 59 in Q4 2018.
- Funds reported $88.1M of ARK Genomic Revolution ETF stock for Q1 2019, up 73% quarter-over-quarter.
- 17 funds opened new ARK Genomic Revolution ETF positions in Q1 2019 and 12 closed out, a net change of +5 holders.
- The largest ARK Genomic Revolution ETF buyer in Q1 2019 was Carroll Financial Associates, an estimated $6.38M added.
- The largest ARK Genomic Revolution ETF seller in Q1 2019 was Arlington Capital Management, an estimated $5.38M sold.
Based on aggregated 13F filings for Q1 2019.